Navigation Links
Syneron Medical Introduces New FDA-Cleared 5mm Spot Size for Treatment of Onychomycosis
Date:8/14/2014

IRVINE, Calif., Aug. 14, 2014 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, announced today the market launch of its proprietary handpiece featuring a new 5-millimeter spot size for the Gentle Pro Nd:YAG Laser Series.

The introduction of this new FDA-cleared handpiece expands the functionality of the GentleYAG® Pro and GentleMax® Pro Nd:YAG laser to treat onychomycosis (nail fungus) in addition to its existing capabilities for hair removal and for the treatment of vascular and pigmented lesions.

Onychomycosis is one of the most commonly diagnosed foot conditions, affecting 10-12 percent of the population1. This prevalent and persistent disorder results in thick, jagged nails that can injure surrounding skin, spawning secondary infections and ulcers. Diabetics are especially at risk with a 34 percent chance of developing fungal nail infection and an increased instance of other complications.2 In those age 70 and up, 50 percent are expected to develop onychomycosis.3

Currently a $1.6 billion market in the United States4, the treatment of nail fungus has been challenging. The previous standard of care has been oral antifungal medications, which carry side effects including the potential for hepatotoxicity (chemical driven liver damage) and a high failure rate. Topical treatments have also resulted in limited success due to their inability to properly penetrate the nail.

Laser therapies like Candela's Gentle Pro Nd:YAG Laser allow physicians to treat onychomycosis symptoms locally without the systemic effects of oral medications. All infectious agents, except prions, can be killed by heat, which makes laser therapy an extremely promising new option for onychomycosis sufferers.

With its precision 5 mm handpiece, the Gentle Pro Nd:YAG Laser raises the temperature under the nail to a level that's inhospitable to fungus in order to increase the appearance of clear nails.

"This new indication for the Gentle Pro series puts Syneron at the forefront of technological advancements designed to meet and surpass our physician partners' standards," said Amit Meridor, Chief Executive Officer of Syneron. "The 5 mm handpiece makes our Gentle Pro laser even more valuable for our customers, expanding patient services with one simple addition."

About Syneron
Syneron Medical Ltd. is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint.  The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under three distinct brands, Syneron, Candela and CoolTouch.  

Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the U.S.  The company markets, services and supports its products in 86 countries.  It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.

For additional information, please visit http://www.syneron-candela.com.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions, market acceptance of new products, and other factors beyond the Company's control and the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Company's most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical makes with the SEC. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.  These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.

Contacts:
Zack Kubow, The Ruth Group  zkubow@theruthgroup.com 646-536-7020
Hugo Goldman, Chief Financial Officer  Hugo.Goldman@syneron.com
Syneron Medical, Public Relations
 pr@syneron.com
Melissa Ben-Yoseph, KELZ PR   Melissa@kelzpr.com  646.450.5359

1 David Pariser, MD, Richard K. Scher, MD, Boni Elewski, MD and Phoebe Rich, MD, "Update on Onychomycosis: Effective Strategies for Diagnosis and Treatment," Global Academy for Medical Education, 2013.
2 Doug Brunk, "Lasers Promising for Onychomychosis Treatment," Skin and Allergy News, October 2013, 15.
3 Brunk, 15.
4 Brunk, 15.

Logo - http://photos.prnewswire.com/prnh/20120528/535447


'/>"/>
SOURCE Syneron Medical Ltd.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions
2. Syneron Medical And Unilever Ventures Create Iluminage Beauty, A Global Joint Venture In Home Beauty Devices
3. Synerons elure Brings Home Allure Magazines Best of Beauty Award, for the Third Consecutive Year
4. Syneron Medical stellt die nächste Generation von Handstücken für die Haarentfernung mit Gentle Pro Laser und elos-Plus-Systemen vor
5. Robert S. Langer, Sc.D., joins eLux Medical Scientific Advisory Board
6. Allan J. Collins, M.D., to join NxStage as Senior Medical Advisor
7. Quanta Establishes Medical Advisory Board of World-Leading Renal Experts
8. Global Medical Devices Market 2014-2018
9. Varian Medical Systems Schedules Investor Meeting at ASTRO in San Francisco
10. Report: Acquisitions Driving Global Medical Device Market
11. Study Helps Medical Education Leaders Navigate the New Regulatory and Financial Landscape
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... May 27, 2016 According to ... hypertension is driving ambulatory blood pressure monitoring system market ... and their ability to respond to different pressure rates, ... can lead to various cardiovascular disorders such as heart ... These diseases are growing in prevalence each year. WHO ...
(Date:5/27/2016)... NEW YORK , May 27, 2016 ... with biotechs, drug manufacturers, health insurance companies all falling ... very small healthcare companies. While not often talked about, ... The United States is by ... the world. Advanced Medical Isotope Corp. (OTC: ADMD), Nutranomics ...
(Date:5/26/2016)... , May 26, 2016   ... software and analytics, network solutions and technology-enabled ... announced it entered into a strategic channel ... of outpatient software solutions and revenue cycle ... specialty hospitals and rehabilitation clinics to optimize ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... ... W.S. Badger Co. Inc ., the maker of certified organic and ... of the best small businesses for new dads by Fatherly, the digital lifestyle guide ... progressive benefits to new parents on the organization’s 2016 Best Places to Work ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... help educate the many who are unaware of the plight of aphasia. In ... run within the “Stroke Awareness” campaign. , The link between stroke and aphasia ...
(Date:5/27/2016)... ... ... With a team of certified experts, Validation Center is ... GMP accreditation, Validation Center is also a registered authority of the international system ... Validation Center is ISO17025 accredited and only offers its clients the latest technology, ...
(Date:5/26/2016)... ... 26, 2016 , ... Intalere, the healthcare industry leader in ... inaugural Member Conference at the Paris Hotel in Las Vegas, Nev., May 17-20, ... America’s healthcare providers. , The conference was highlighted by the announcement of the ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... has a significant negative impact on long-term patient survival, reports a team of ... published online this week in the Journal of Thoracic and Cardiovascular Surgery, provide ...
Breaking Medicine News(10 mins):